Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) shares traded down 5.4% during mid-day trading on Wednesday . The company traded as low as C$6.86 and last traded at C$6.86. 1,750 shares were traded during mid-day trading, an increase of 141% from the average session volume of 725 shares. The stock had previously closed at C$7.25.
Neuren Pharmaceuticals Stock Down 5.4 %
The stock has a fifty day moving average of C$8.13 and a 200-day moving average of C$8.41.
Neuren Pharmaceuticals Company Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
Read More
- Five stocks we like better than Neuren Pharmaceuticals
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Alphabet’s Officially In A Bear Market—Time To Buy?
- ETF Screener: Uses and Step-by-Step Guide
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
